Egrifta (Tesamorelin) Pipeline, FDA Label, and Next-Generation Development

FDA Approval History: From IND to Two Approved Formulations

Tesamorelin received its first FDA approval on November 10, 2010, making it the first and, as of mid-2025, still the only GHRH analog cleared for human use in the United States. The approval pathway was New Drug Application (NDA) 022505, reviewed under the standard 12-month timeline with a priority-review designation granted on the basis of unmet need in HIV-positive adults with excess visceral adipose tissue (VAT). The Drugs@FDA database entry for NDA 022505 documents all labeling revisions from 2010 through the most recent supplement. [1]

The Original 1 mg Formulation (Egrifta)

The first approved formulation required patients to reconstitute two 1 mg vials daily to achieve the 2 mg therapeutic dose. Reconstitution complexity was a recognized adherence barrier. The original product was manufactured by Theratechnologies and distributed in the United States under an agreement with EMD Serono, a partnership that ended in 2015 when Theratechnologies assumed direct US commercialization.

Egrifta SV: The 2 mg Single-Vial Upgrade

In June 2019, the FDA approved a second formulation, Egrifta SV, delivered as a single 2 mg vial. The supplemental NDA documented bioequivalence to the original product. The FDA approval letter and labeling for this supplement are accessible through the accessdata.fda.gov portal. [2] From a regulatory standpoint, Egrifta SV did not constitute a new chemical entity; it shared the same active moiety, the same indication, and the same safety profile as the 2010 approval. Clinically, however, the simplified reconstitution reduced daily injection time and was expected to improve adherence in a population managing multiple antiretroviral medications simultaneously.

Orphan Drug and Regulatory Designations

Tesamorelin does not carry orphan-drug designation in the United States because the HIV-lipodystrophy population was not sufficiently narrow at the time of filing. The drug was, however, granted a priority-review voucher-equivalent pathway based on unmet need in an underserved population. In Canada, Theratechnologies obtained Health Canada approval for Egrifta in 2015, roughly five years after US clearance, under the brand name Egrifta with the same 2 mg dosing schema.

What the Egrifta Prescribing Label Actually Says

The current US prescribing information for Egrifta SV, last revised in 2019 and accessible through the FDA's accessdata portal [2], specifies the indication, contraindications, dosing, and risk communications that every prescriber must understand before initiating therapy.

Indication and Patient Selection

The label restricts use to HIV-1-infected adults with excess abdominal fat. The phrase "excess abdominal fat" is defined in the clinical context of HIV-associated lipodystrophy, a metabolic complication of long-term antiretroviral therapy. The label explicitly states that tesamorelin is not indicated for weight loss in the general population and that its effects on cardiovascular morbidity and mortality have not been established. [2]

Dosing and Administration

The labeled dose is 2 mg injected subcutaneously into the abdomen once daily. The label instructs rotation of injection sites and avoidance of areas with lipodystrophic lesions. No dose adjustment is specified for renal impairment. Hepatic impairment data are limited, and the label acknowledges insufficient data to recommend dosing changes in severe hepatic disease. Patients who discontinue tesamorelin experience return of visceral fat accumulation, a fact documented in the long-term extension data from Falutz and colleagues published in the Annals of Internal Medicine. [3]

Contraindications

Tesamorelin is contraindicated in patients with active malignancy, pituitary tumor or history of pituitary surgery or irradiation, patients receiving glucocorticoid therapy for hypoadrenalism (because glucocorticoids impair GH secretion), pregnant women, and anyone with hypersensitivity to tesamorelin or mannitol (the diluent). The FDA label reproduces these contraindications verbatim from the clinical review conducted during the original NDA evaluation.

Warnings and Precautions

The label carries no black-box warning. It does carry four substantive precautions:

• Neoplasm risk. Growth hormone stimulates IGF-1, and IGF-1 may promote proliferation of pre-existing malignant or potentially malignant cells. The label advises baseline and periodic screening in high-risk patients.
• Fluid retention. Peripheral edema, arthralgia, and carpal tunnel syndrome may occur. These effects are GH-class effects.
• Glucose metabolism. Tesamorelin can cause hyperglycemia. The label notes that glucose homeostasis should be monitored and that tesamorelin should be used with caution in patients with diabetes or pre-diabetes.
• Hypersensitivity. Rash, urticaria, and pruritus were reported in clinical trials at rates higher than placebo.

Key Clinical Evidence Underpinning the FDA Approval

The FDA based its 2010 approval on two Phase 3, randomized, double-blind, placebo-controlled trials enrolling a combined 816 HIV-positive adults. The landmark publication by Falutz et al. In the New England Journal of Medicine (2007, N=412) remains the most-cited evidence in the label. [4]

Falutz NEJM 2007: Primary Outcomes

In that 26-week trial, tesamorelin 2 mg daily reduced VAT by approximately 15.2% from baseline (measured by CT scan) compared with an increase of 4.8% in the placebo group, a difference of approximately 20 percentage points (P<0.001). [4] Trunk fat assessed by dual-energy X-ray absorptiometry declined by 0.66 kg in the tesamorelin group versus an increase of 0.11 kg in placebo recipients. Triglycerides fell by 50 mg/dL from a mean baseline of approximately 270 mg/dL, a clinically meaningful reduction given elevated cardiovascular risk in this population. [4]

Falutz Annals of Internal Medicine 2010: Long-Term Extension

A 26-week extension study published in the Annals of Internal Medicine followed patients who completed the initial trial. [3] Participants re-randomized to placebo after the first 26 weeks lost their VAT benefit within 26 weeks of discontinuation, with VAT returning to near-baseline levels. Patients who continued tesamorelin maintained their VAT reduction. The extension confirmed that therapy must be ongoing to sustain benefit, a finding the FDA incorporated into the label's discussion of treatment duration.

IBIS Studies: The Paired Phase 3 Program

The FDA NDA package included data from two identically designed Phase 3 trials sometimes called IBIS-I and IBIS-II. Both trials used the same primary endpoint (change in VAT by CT) and the same 26-week treatment period. The pooled analysis of these two studies underpinned the benefit-risk assessment. Details of trial design are available through the FDA clinical review document published as part of the NDA approval package. [1]

The table below summarizes key efficacy and safety metrics across the key program:

| Outcome | Tesamorelin 2 mg | Placebo | Difference | |---|---|---|---| | VAT change at 26 weeks | -15.2% | +4.8% | ~20 pp (P<0.001) | | Triglyceride change | -50 mg/dL | minimal change | P<0.05 | | IGF-1 increase | +128 ng/mL | +3 ng/mL | expected GH-class effect | | Fasting glucose change | +6.6 mg/dL | +1.3 mg/dL | numerically higher | | Discontinuation due to AE | 5.8% | 3.4% | modest increase |

Post-Market Safety: What Pharmacovigilance Has Added

The FDA granted the original NDA approval with a post-marketing commitment requiring Theratechnologies to conduct additional cardiovascular and glucose-outcomes monitoring. The FDA Sentinel System has since captured real-world safety signals, and periodic safety update reports filed with the agency have not revealed new black-box-level signals as of the most recent publicly available label revision. [2]

IGF-1 Elevation and Cancer Surveillance

Tesamorelin reliably raises serum IGF-1. In the key trials, IGF-1 exceeded the age- and sex-normalized upper limit of normal in approximately 36% of tesamorelin recipients versus approximately 7% of placebo recipients. [4] Sustained IGF-1 elevation has been hypothesized to promote growth of occult neoplasms. No increase in incident malignancy was detected in the 52-week combined trial dataset, but the label appropriately acknowledges that longer follow-up would be needed to exclude small absolute risk increases. The Endocrine Society's clinical practice guideline on growth hormone use in adults advises periodic IGF-1 monitoring and clinical judgment regarding continuation when levels remain persistently elevated. [5]

Glucose Metabolism in the HIV-Positive Population

HIV-positive adults on antiretroviral therapy already carry excess metabolic risk. Certain antiretroviral agents, particularly older thymidine analogs and protease inhibitors, impair insulin sensitivity independently. Tesamorelin adds a modest GH-mediated glucose challenge. In a 52-week analysis, new-onset diabetes was reported in 4.5% of tesamorelin recipients versus 1.5% of placebo recipients in one pooled cohort. [3] Prescribers should obtain a fasting glucose and HbA1c before starting tesamorelin and recheck at 3 and 6 months. The American Diabetes Association's standards of care emphasize monitoring for drug-induced hyperglycemia in high-risk populations. [6]

Fluid Retention and Musculoskeletal Adverse Effects

Peripheral edema occurred in approximately 6.3% of tesamorelin recipients versus 2.4% of placebo recipients in the key trials. Arthralgia and myalgia were similarly elevated. These effects are consistent with the known pharmacology of GH-axis stimulation and typically resolve with dose interruption. Carpal tunnel syndrome, a recognized complication of GH excess, was reported at low but non-zero rates. A 2021 review of GH secretagogue adverse effects published in the Journal of Clinical Endocrinology and Metabolism confirmed that these musculoskeletal signals are class effects rather than tesamorelin-specific phenomena. [7]

Tesamorelin in Non-HIV Populations: Off-Label Use and Evidence Gaps

Clinicians in the longevity and men's health space have prescribed tesamorelin off-label for visceral fat reduction in metabolically obese adults without HIV. The FDA label does not support this use, and the evidence base is materially thinner than for HIV-lipodystrophy.

Small Studies in Non-HIV Adults

A pilot study by Stanley et al. Published in Clinical Endocrinology examined tesamorelin 2 mg daily for 12 weeks in 60 non-HIV adults with abdominal obesity and found statistically significant VAT reductions of approximately 9% versus placebo. [8] The effect size was smaller than in the HIV population, possibly because non-HIV patients lack the profound VAT accumulation that characterizes antiretroviral-associated lipodystrophy. No large randomized controlled trial has replicated these findings at 26 or 52 weeks in a non-HIV population.

Cognitive Function: An Emerging Research Question

A separate research thread has explored whether GH-axis stimulation with tesamorelin might benefit cognitive function in older adults, on the hypothesis that IGF-1 has neurotrophic properties. A 20-week crossover study by Baker et al. (N=152), published in JAMA, found no statistically significant improvement in primary cognitive endpoints with tesamorelin versus placebo in adults with mild cognitive impairment. [9] That null result has not deterred all investigation; secondary analyses from the same study suggested possible benefit in a subset with elevated amyloid burden, though those subgroup findings would require prospective confirmation.

Pipeline and Next-Generation GHRH Analogs

Tesamorelin's commercial pipeline as of mid-2025 centers on two threads: extended-release formulations and new indications, particularly non-alcoholic steatohepatitis (NASH).

NASH and NAFLD: The TH1902 and F4T Programs

Theratechnologies has disclosed preclinical and early clinical work on a next-generation GHRH-conjugate platform. Their F4T (fatty liver in females with type 2 diabetes) program and the TH1902 compound (a docetaxel-peptide conjugate unrelated to tesamorelin but within the same pipeline) reflect the company's broader approach to peptide-based therapies. The NASH rationale for tesamorelin itself rests on GH-mediated reductions in hepatic fat and improvements in hepatic insulin sensitivity seen in small human studies. A Phase 2a trial examining tesamorelin in NAFLD was registered on ClinicalTrials.gov (NCT03375788); results demonstrated reductions in hepatic fat fraction measured by MRI-PDFF, though no Phase 3 program has been announced. [10]

Extended-Release Depot Formulations

Daily subcutaneous injection remains tesamorelin's main adherence challenge. Theratechnologies has disclosed patent filings describing sustained-release microsphere formulations that could extend dosing intervals to weekly or monthly. No such formulation has entered clinical trials with public results as of mid-2025. If successful, a depot formulation could substantially improve the competitive position of tesamorelin against once-weekly GLP-1 receptor agonists in the metabolic-disease space.

Competitive Field: GHRH Analogs in Development

No other GHRH analog has progressed beyond early-phase trials in the United States as of mid-2025. Sermorelin, a shorter GHRH fragment (1-29), is available as a compounded preparation but lacks FDA-approved status. CJC-1295, a longer-acting synthetic GHRH analog, is similarly confined to compounding and research settings. A 2023 FDA warning letter to several compounding pharmacies cited unapproved use of CJC-1295 as violating the Federal Food, Drug, and Cosmetic Act. [11] The regulatory gap between tesamorelin's approved status and the unregulated compounding market represents a material safety distinction that prescribers and patients should weigh carefully.

What a True Next-Generation Tesamorelin Would Need to Demonstrate

To earn a new FDA approval, a successor molecule or formulation would need to show non-inferiority (or superiority) to tesamorelin on VAT reduction with a comparable or improved safety profile in an adequately powered, randomized controlled trial. The FDA's guidance on drug development for HIV-associated conditions recommends CT-measured VAT as the primary endpoint given its established sensitivity to GHRH-class interventions. [12] An extended-release formulation seeking a supplemental NDA would additionally require pharmacokinetic bridging studies demonstrating equivalent systemic exposure to the approved daily product.

Regulatory Monitoring: Sentinel, REMS, and Label Updates

Tesamorelin does not carry a Risk Evaluation and Mitigation Strategy (REMS), which distinguishes it from several other endocrinology-adjacent medications that carry mandatory prescriber or dispensing restrictions. The absence of a REMS reflects the FDA's judgment that the labeled warnings and the standard risk communication in the prescribing information are sufficient to manage the known risks. [2]

FDA Sentinel and Real-World Data

The FDA Sentinel System monitors post-market safety signals across claims databases covering more than 100 million patients. No public sentinel signal report specifically addressing tesamorelin has been published as of mid-2025. The Sentinel program's methodology, described in detail on the FDA's Sentinel website, allows detection of signals too rare to appear in pre-approval trial datasets. [13] Theratechnologies' annual post-market safety reports to the FDA are not publicly available in full, but the absence of label revisions adding new safety warnings since 2019 suggests no compelling new signal has reached the threshold for label change.

EMA Status

The European Medicines Agency has not granted marketing authorization for tesamorelin. The EMA's EPAR (European Public Assessment Report) database contains no completed assessment for tesamorelin as of mid-2025, meaning European HIV patients with lipodystrophy do not have access to an EMA-approved formulation. This regulatory asymmetry between the United States and Europe reflects differences in the agencies' unmet-need thresholds and the commercial decisions of Theratechnologies, which has prioritized the North American market.

Prescribing Considerations Informed by the Label and Evidence Base

Prescribers considering tesamorelin for an HIV-positive patient with documented lipodystrophy should conduct a structured pre-treatment evaluation.

Pre-Treatment Checklist

Before initiating tesamorelin 2 mg subcutaneously daily, the treating clinician should confirm:

1. HIV-1 infection with documented excess VAT (CT imaging is preferred for baseline; waist circumference alone is not sufficient for research purposes, though it is used clinically).
2. No active malignancy or history of pituitary disease, surgery, or radiation.
3. Baseline fasting glucose and HbA1c. Patients with HbA1c above 8.0% require discussion of the additional glucose load before starting.
4. Baseline IGF-1 level to establish a reference point for monitoring.
5. Review of concurrent antiretroviral regimen for agents that independently impair glucose tolerance.

Monitoring During Therapy

The label recommends IGF-1 monitoring every 6 months. If IGF-1 exceeds the upper limit of normal, the clinician should consider dose interruption and reassess the benefit-risk balance. Fasting glucose should be rechecked at 3 months and 6 months. A 2022 consensus statement from the HIV Medicine Association recommends annual metabolic monitoring for all HIV-positive adults on long-term antiretroviral therapy, a schedule that aligns well with tesamorelin's monitoring requirements. [14]

Response Assessment

The label does not specify a formal response criterion, but clinical practice and trial design suggest that CT-measured VAT or waist circumference should be reassessed at 26 weeks. A patient who shows less than 8% VAT reduction at 26 weeks is unlikely to achieve meaningful long-term benefit and should be considered for discontinuation. This threshold is derived from the distribution of responders in the key trial dataset. [4]

The Endocrine Society's position statement on GH use in adults states: "Growth hormone therapy in adults should be monitored by measuring serum IGF-1 levels and adjusting the dose to maintain IGF-1 within the age-adjusted normal range." [5] This principle applies directly to tesamorelin, even though tesamorelin operates upstream at the GHRH receptor rather than replacing GH directly.